

Do you work with women who have been prescribed **CDK4/6 inhibitors** for early stage ER+ve breast cancer?



Help us understand what support and help women currently receive for CDK4/6 inhibitors in the early breast cancer adjuvant setting by participating in an **online interview or focus group (approx. 1 hour)**.

To find out more about the SWEET-PLUS study (NIHR207952) please:

- Email: pearlin.teow@ncl.ac.uk
- Or leave your contact details [here](#) and we will be in touch with more information about the study